Therefore, the non-invasive identification of IDH mutant gliomas using 1H-MRS plays an important role in patient counseling for therapeutic intervention and prognostication and could be utilized as a pharmacodynamic indicator to monitor treatment response [17,18]. This evidence concerns the gene IDH1 and central nervous system cancer.